Results 51 to 60 of about 13,617 (225)

A Delphi Consensus on Clinical Features, Diagnosis, and Treatment of Chronic Rhinosinusitis With Nasal Polyps in the ASEAN Region

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life.
Baharudin Abdullah, Revadi Govindaraju, Salina Husain, Jin Keat Siow, Pongsakorn Tantilipikorn, Neville Wei Yang Teo, De Yun Wang, Deasi Anggraini, Tze Choong Charn, Chao‐Wu David Chin, Dichapong Kanjanawasee, Maung Maung Khaing, Jern‐Lin Leong, Luan Viet Tran, Harvinder Singh, Ing Ping Tang, Kim Thye Mark Thong, Gil M. Vicente, Yoke Yeow Yap, Soma Subramaniam   +19 more
wiley   +1 more source

Update on optimal use of omalizumab in management of asthma

, 2011
Girolamo Pelaia1, Luca Gallelli1, Teresa Renda1, Pasquale Romeo1, Maria Teresa Busceti1, Rosa Daniela Grembiale1, Rosario Maselli1, Serafino Antonio Marsico2, Alessandro Vatrella31Department of Experimental and Clinical Medicine, University Magna Gr& ...
Gallelli L, Vatrella A, Romeo P, Busceti MT, Grembiale RD, Marsico SA, VATRELLA, Alessandro, Maselli R, Renda T, Pelaia G   +9 more
core   +1 more source

Obesity and Its Impact on Endoscopic Sinus Surgery Outcomes in Patients With Chronic Rhinosinusitis With Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Purpose The rising prevalence of obesity introduces challenges in surgical contexts, including endoscopic sinus surgery (ESS) for chronic rhinosinusitis with nasal polyps (CRSwNP). However, the impact of obesity on ESS outcomes remains underexplored. This study aims to evaluate the association between obesity and surgical complexity, operative
Hen Chaushu, Narin Nard Carmel Neiderman, Yuval Presman, Alexandra Dorman, Roni Vass, Nidal Muhanna, Avraham Abergel   +6 more
wiley   +1 more source

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada

Patient Preference and Adherence, 2020
Jason K Lee,1 Suvina Amin,2 Michelle Erdmann,3 Atif Kukaswadia,4 Jelena Ivanovic,5 Aren Fischer,4 Alain Gendron6 1Clinical Immunology and Allergy, Internal Medicine, Evidence Based Medical Educator Inc.
Lee JK, Amin S, Erdmann M, Kukaswadia A, Ivanovic J, Fischer A, Gendron A   +6 more
doaj  

Serum free IgE guided dose reduction of omalizumab: a case report

Allergy, Asthma & Clinical Immunology, 2017
Background Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for ...
Yasuhiro Gon, Reiko Ito, Shuichiro Maruoka, Kenji Mizumura, Yutaka Kozu, Hisato Hiranuma, Yuko Iida, Sotaro Shikano, Shu Hashimoto   +8 more
doaj   +1 more source

Omalizumab, an anti-immunoglobulin E antibody: state of the art

, 2014
Cristoforo Incorvaia,1 Marina Mauro,2 Marina Russello,2 Chiara Formigoni,3 Gian Galeazzo Riario-Sforza,1 Erminia Ridolo41Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, Italy; 2Allergy Unit, 3Scientific Library ...
Formigoni C, M. Mauro, RIDOLO, Erminia, Russello M, Riario-Sforza GG, C. Incorvaia, Mauro M, Ridolo E, M. Russello, G.G. Riario Sforza, Incorvaia C, C. Formigoni   +11 more
core   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Journal of Allergy and Clinical Immunology: Global
Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy.
Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD   +7 more
doaj   +1 more source

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine.
Ana G. Lopes, Marianlie Navarro, Carmem Botelho, Maria J. Guimarães, Catarina Cerqueira, Joana Gomes, Celeste Brito   +6 more
doaj  

Thyroid Autoimmunity in CSU: A Potential Marker of Omalizumab Response? [PDF]

, 2023
The response of severe chronic spontaneous urticaria (CSU) to omalizumab largely depends on the autoimmune or autoallergic endotype of the disease. Whether thyroid autoimmunity may predict omalizumab response along with total IgE in CSU is still unclear.
Cugno, Massimo, Riccardo Asero, Paolo Calzari, Massimo Cugno, Consonni, Dario, Calzari, Paolo, Ferrucci, Silvia Mariel, Silvia Mariel Ferrucci, Asero, Riccardo, Dario Consonni   +9 more
core   +1 more source